EUR million | Note | 2024 | 2023 |
Net sales | 4.2. | ||
Other operating income | 4.2. | ||
Materials and supplies | 4.3. | - | - |
Employee benefit expenses | 4.4. | - | - |
Other operating expenses | 4.3. | - | - |
Depreciation, amortisation and impairments | 6.1./6.2. | - | - |
EBIT | - | ||
Financial income and expenses | 8.1. | - | - |
Share of results in joint venture | 10.4. | - | - |
Profit before taxes | - | - | |
Income taxes | 9.1. | - | - |
Profit for the period | - | - |
| Other comprehensive income | |||
| Items which may be reclassified subsequently to profit or loss: | |||
| Translation differences recognised in comprehensive income | |||
during the reporting period | - | ||
Cash flow hedge | 8.3. | - | - |
Income tax relating to other comprehensive income | 9.1. | ||
- | - | ||
| Items which will not be reclassified to profit or loss: | |||
Financial assets recognised at fair value through other comprehensive income | 8.2. | - | - |
Actuarial gains/losses on defined benefit plans | 4.4. | - | |
Income tax relating to other comprehensive income | 9.1. | - | |
- | - | ||
Total comprehensive income for the period | - | - | |
Profit attributable to Parent company shareholders | - | - |
EUR million | Note | 2024 | 2023 |
| Total comprehensive income attributable to | |||
Parent company shareholders | - | - | |
| Earnings per share attributable to parent company shareholders: | |||
Basic, EUR | 8.5. | - | - |
Diluted, EUR | 8.5. | - | - |
EUR million | Note | 2024 | 2023 | EUR million | Note | 2024 | 2023 |
| ASSETS | EQUITY AND LIABILITIES | ||||||
| Non-current assets | Equity | ||||||
Property, plant and equipment | 6.1. | Share capital | 8.4. | ||||
Goodwill | 6.2. | Fair value reserve | 8.4. | ||||
Other intangible assets | 6.2. | Contingency fund | 8.4. | ||||
Investments in joint ventures | 10.4. | Invested unrestricted equity reserve | 8.4. | ||||
Other non-current assets | 6.3. | Other reserves | 8.4. | ||||
Deferred tax assets | 9.2. | Translation differences | 8.4. | - | - | ||
Non-current assets total | Retained earnings | ||||||
Equity attributable to the parent company shareholders | |||||||
| Current assets | |||||||
Inventories | 5.2. | Non-current liabilities | |||||
Trade receivables | 5.1. | Deferred tax liabilities | 9.2. | ||||
Income tax receivables | 5.1. | Pension obligations | 4.4. | ||||
Other receivables | 5.1. | Interest-bearing liabilities | 8.2. | ||||
Cash and cash equivalents | 8.2. | Other non-current liabilities | 5.3. | ||||
Assets held for sale | 10.3. | Non-current liabilities total | |||||
Current assets total | |||||||
| Current liabilities | |||||||
ASSETS TOTAL | Trade payables | 5.3. | |||||
Interest-bearing liabilities | 8.2. | ||||||
Income tax payables | 5.3. | ||||||
Other current liabilities | 5.3. | ||||||
Liabilities related to assets held for sale | 10.3. | ||||||
Current liabilities total | |||||||
EQUITY AND LIABILITIES TOTAL |
EUR million | Note | 2024 | 2023 | EUR million | Note | 2024 | 2023 |
| Net cash flow from operating activities | Change in other current financing * | 8.2. | - | - | |||
Profit for the period | - | - | Amortisations of lease liabilities | 8.2. | - | - | |
| Adjustments | Purchasing of own shares | - | - | ||||
Depreciation and amortisation | 6.1./6.2. | Dividends paid | - | - | |||
Impairment | 6.1./6.2. | Net cash flow from financing activities | - | - | |||
Share of results in joint venture | 6.3. | ||||||
Financial income and expenses | 8.1. | Net change in cash and cash equivalents | - | - | |||
Income taxes | 9.1. | ||||||
Change in pension asset and pension obligation | Cash and cash equivalents at the beginning of the period | ||||||
Other adjustments | Translation differences | - | |||||
Net change in cash and cash equivalents | - | - | |||||
Cash and cash equivalents at the end of the period | 8.2. | ||||||
| Change in working capital | |||||||
Change in current receivables increase (-)/ decrease (+) | - | ||||||
Change in inventories increase (-)/ decrease (+) | - | - | |||||
| Change in non-interest-bearing current liabilities increase (+)/ decrease | |||||||
(-) | |||||||
- | |||||||
Interest received | |||||||
Interest paid | - | - | |||||
Other financial income and expenses | - | - | |||||
Income taxes paid | - | - | |||||
Net cash flow from operating activities | |||||||
| Net cash flow from investing activities | |||||||
Investments in property, plant and equipment and intangible assets | 6.1./6.2. | - | - | ||||
Proceeds from sales of property, plant and equipment and intangible assets | 6.1./6.2. | ||||||
Net cash flow from investing activities | - | - | |||||
| Net cash flow from financing activities | |||||||
Proceeds from long-term loans | 8.2. | ||||||
Repayments of long-term loans | 8.2. | - | - | ||||
Repayments of short-term loans | 8.2. | - |
| Translation | Retained | |||||
EUR million | Note | Share capital | Funds | differences | earnings | Equity total |
Equity 1 January 2023 | - | |||||
| Comprehensive income for the period | ||||||
Net profit for the period | - | - | ||||
| Other comprehensive income: | ||||||
Financial assets recognised at fair value through other comprehensive income: | ||||||
Change in fair value | 8.2. | - | - | |||
Cash flow hedge | 8.3. | - | - | |||
Actuarial gains and losses | 4.4. | - | - | |||
Income tax relating to other comprehensive income | 9.1. | |||||
Translation difference | ||||||
Comprehensive income for the period, total | - | - | - | |||
| Transactions with owners | ||||||
Dividend distribution | 8.5. | - | - | |||
Share-based incentive | 4.4. | |||||
Purchase of own shares | - | - | ||||
Transactions with owners, total | - | - | ||||
Equity 31 December 2023 | - | |||||
| Comprehensive income for the period | ||||||
Net profit for the period | - | - | ||||
| Other comprehensive income: | ||||||
Financial assets recognised at fair value through other comprehensive income: | ||||||
Change in fair value | 8.2. | - | - | |||
Cash flow hedge | 8.3. | - | - | |||
Actuarial gains and losses | 4.4. | |||||
Income tax relating to other comprehensive income | 9.1. | - | ||||
Translation difference | - | - | ||||
Comprehensive income for the period, total | - | - | - | - | ||
| Transactions with owners | ||||||
Dividend distribution | 8.5. | - | - | |||
Share-based incentive | 4.4. | |||||
Purchase of own shares | - | - | ||||
Transactions with owners, total | - | - | ||||
Equity 31 December 2024 | - |
Item | Nature of management judgement | Note |
Revenue recognition | Principal vs. agent assessment | 4.2. |
Inventories | Principal vs. agent assessment | 5.2. |
| Changes in the fair value of the investment | ||
| Other shares | (Doktor.se) | 6.3. |
Lease liabilities | Determining lease term for contracts | 7.1. |
Item | Nature of assumptions and estimates | Note |
Defined benefits | Key actuarial assumptions | 4.4. |
| Projection parameters and key assumptions | ||
| used in determining the underlying | ||
| Impairment testing | recoverable amounts | 6.2. |
Impairment testing | Events or change in circumstances | 10.4. |
| EUR million | |||||
2024 | Note | Distribution | Wholesale | Group items | Total |
External invoicing | 3,456.5 | 315.3 | - | 3,771.8 | |
Internal invoicing | - | 0.6 | -0.6 | 0.0 | |
Invoicing | 3,456.5 | 315.9 | -0.6 | 3,771.8 | |
Sales to external customers | 1,364.7 | 315.0 | - | 1,679.7 | |
Sales to other segments | - | 0.6 | -0.6 | 0.0 | |
Net sales | 4.2. | 1,364.7 | 315.6 | -0.6 | 1,679.7 |
EBIT | 20.4 | 8.5 | -15.3 | 13.6 | |
Adjusted EBIT | 19.0 | 9.5 | -6.8 | 21.7 | |
Non-current assets | 60.3 | 20.0 | 232.4 | 312.8 | |
Investments | 6.1./6.2. | 2.6 | 0.2 | 0.1 | 2.9 |
Depreciation, amortisation and impairments | 6.1./6.2. | 8.6 | 3.0 | 2.0 | 13.6 |
Average number of personnel, full time equivalents | 447 | 292 | 74 | 812 | |
| 2023 | |||||
External invoicing | 3,282.5 | 305.3 | - | 3,587.7 | |
Internal invoicing | - | 0.9 | -0.9 | 0.0 | |
Invoicing | 3,282.5 | 306.2 | -0.9 | 3,587.7 | |
Sales to external customers | 1,189.0 | 304.8 | - | 1,493.8 | |
Sales to other segments | - | 0.9 | -0.9 | 0.0 | |
Net sales | 4.2. | 1,189.0 | 305.7 | -0.9 | 1,493.8 |
EBIT | -6.9 | 8.6 | -7.0 | -5.3 | |
Adjusted EBIT | 14.5 | 8.9 | -6.8 | 16.7 | |
Non-current assets | 71.5 | 8.9 | 264.9 | 345.3 | |
Investments | 6.1./6.2. | 1.6 | 0.2 | 1.7 | 3.5 |
Depreciation, amortisation and impairments | 6.1./6.2. | 31.7 | 3.6 | 0.1 | 35.4 |
Average number of personnel, full time equivalents | 450 | 268 | 82 | 800 |
| Adjusting items included in EBIT | ||
EUR million | 2024 | 2023 |
Restructuring costs | -0.1 | -0.2 |
Impairments and write-downs | -1.9 | -21.6 |
ERP investment related implementation costs in cloud computing arrangement | -5.9 | - |
Service agreement settlement | -0.9 | - |
Compensation from court appeal | 1.4 | - |
Other | -0.8 | -0.2 |
Total | -8.1 | -21.9 |
| Geographical information | ||||
| EUR million | Other | |||
2024 | Sweden | Finland | countries | Total |
Sales to external customers | 1,093.8 | 549.8 | 36.2 | 1,679.7 |
Non-current assets* | 29.2 | 283.7 | - | 312.8 |
Investments | 1.0 | 1.8 | - | 2.9 |
Average number of personnel, full time equivalents | 394 | 418 | - | 812 |
| EUR million | Other | |||
2023 | Sweden | Finland | countries | Total |
Sales to external customers | 836.7 | 536.5 | 120.7 | 1,493.8 |
Non-current assets* | 55.1 | 290.2 | - | 345.3 |
Investments | 0.8 | 2.7 | - | 3.5 |
Average number of personnel, full time equivalents | 389 | 411 | - | 800 |
EUR million | 2024 | 2023 |
Purchases during the period | 1,535.5 | 1,348.1 |
Change in inventories | -16.6 | -13.8 |
Products for own use | -0.1 | -0.1 |
Foreign exchange differences | 0.4 | -0.1 |
Total | 1,519.3 | 1,334.1 |
| Materials and supplies by currency | ||
| 2024 | ||
Million | SEK | EUR |
Sweden | 11,782.7 | 1 030.6 |
Finland | 488.6 | |
Total | 1,519.3 | |
| 2023 | ||
Million | SEK | EUR |
Sweden | 9,857.4 | 858.7 |
Finland | 475.3 | |
Total | 1,334.1 |
| Other operating expenses | ||
EUR million | 2024 | 2023 |
Freights and other variable costs | 30.2 | 32.4 |
Marketing | 0.7 | 0.4 |
Information management | 9.9 | 9.3 |
Premises | 5.7 | 5.9 |
External services | 25.7 | 21.8 |
Other operating expenses | 9.4 | 9.9 |
Total | 81.6 | 79.8 |
| Audit fees | ||
EUR million | 2024 | 2023 |
| To member firms of KPMG network | ||
Fees for statutory audit | 0.3 | 0.2 |
Fees for other audit assignments | 0.1 | 0.0 |
Fees for other services | 0.0 | 0.0 |
Total | 0.4 | 0.3 |
| EUR million | |||
2024 | Distribution | Wholesale | Total |
Services and products | 1,302.3 | 244.0 | 1,546.4 |
Other* | 62.4 | 70.9 | 133.3 |
Total | 1,364.7 | 315.0 | 1,679.7 |
| EUR million | |||
2023 | Distribution | Wholesale | Total |
Services and products | 1,121.4 | 234.2 | 1,355.6 |
Other* | 67.7 | 70.6 | 138.2 |
Total | 1,189.0 | 304.8 | 1,493.8 |
EUR million | 31 Dec 2024 | 31 Dec 2023 |
Advances received from pharmacies | 7.9 | 10.4 |
Advances received related to other services | 0.1 | 0.2 |
Total | 8.0 | 10.6 |
EUR million | 2024 | 2023 |
Gains on sales of tangible and intangible assets | - | 0.0 |
Rental income | 0.1 | 0.2 |
Service charges | 1.4 | 1.3 |
Other operating income | 2.9 | 1.4 |
EUR million | 2024 | 2023 |
Total | 4.5 | 2.9 |
| Employee benefit expenses | ||
EUR million | 2024 | 2023 |
Wages, salaries and bonuses | 42.5 | 39.8 |
Share-based payments | 0.1 | 0.5 |
| Pension costs | ||
Defined contribution plans | 5.6 | 5.2 |
Defined benefit plans | 0.5 | 0.3 |
Other personnel expenses | 7.3 | 7.0 |
Total | 56.1 | 52.8 |
| Net defined benefit liability in the statement of financial position is | ||
| defined as follows: | ||
EUR million | 2024 | 2023 |
Present value of funded obligations | 14.7 | 14.8 |
Fair value of plan assets | -1.4 | -1.4 |
Deficit/surplus | 13.3 | 13.4 |
Net liability (+) / assets (-) in the statement of financial position | 13.3 | 13.4 |
| Change in defined benefit obligation and plan assets: | |||
| Present value | |||
| of funded | Fair value of | ||
| EUR million | obligation | plan assets | Total |
1 Jan 2023 | 13.2 | -1.4 | 11.8 |
Current service cost | 0.4 | - | 0.4 |
Interest cost or income | 0.5 | -0.1 | 0.4 |
14.1 | -1.5 | 12.6 | |
| Remeasurements | |||
| Actuarial gains (-) and losses | |||
(+) arising from changes in demographical assumptions | 0.2 | - | 0.2 |
| Actuarial gains (-) and losses (+) | |||
| arising from changes in financial | |||
assumptions | 0.7 | 0.1 | 0.8 |
Experience profits (-) or losses (+) | 0.5 | - | 0.5 |
15.4 | -1.4 | 14.0 | |
Differences in foreign exchange rates | 0.1 | - | 0.1 |
| Contributions | |||
Plan participants | - | -0.1 | -0.1 |
| Expenses arising from the plans | |||
Benefits paid | -0.7 | 0.2 | -0.5 |
31 Dec 2023 | 14.8 | -1.4 | 13.4 |
Current service cost | 0.6 | - | 0.6 |
Interest cost or income | 0.5 | -0.1 | 0.4 |
15.9 | -1.4 | 14.5 | |
| Remeasurements | |||
| Actuarial gains (-) and losses (+) | |||
| arising from changes in financial | |||
assumptions | -0.1 | 0.0 | -0.1 |
Experience profits (-) or losses (+) | -0.1 | - | -0.1 |
15.7 | -1.4 | 14.3 |
| Present value | |||
| of funded | Fair value of | ||
| EUR million | obligation | plan assets | Total |
Differences in foreign exchange rates | -0.4 | - | -0.4 |
| Contributions | |||
Plan participants | - | -0.1 | -0.1 |
| Expenses arising from the plans | |||
Benefits paid | -0.6 | 0.1 | -0.5 |
31 Dec 2024 | 14.7 | -1.4 | 13.3 |
Significant actuarial assumptions 31 Dec: | 2024 | 2023 | |
Discount rate (%) | 3.30 | 3.10-4.00 | |
Salary increases (%) | 2.30-3.45 | 2.80-3.40 |
| Sensitivity of the defined benefit obligation to changes in the most | ||
| significant assumptions: | ||
| Change in assumption | Effect of change | |
| Assumption | as percentage point | in assumption % |
Decrease in discount rate | -0.5 | increase by 10.1 |
Increase in discount rate | +0.5 | reduce by 9.0 |
Increase in salaries | +0.5 | increase by 2.2 |
Increase in benefits | +0.5 | increase by 10.0 |
EUR million | 2024 | 2023 |
Trade receivables | 247.1 | 259.5 |
Income tax receivables | - | 0.6 |
Prepaid expenses and accrued income | 2.3 | 2.0 |
VAT receivables | 8.2 | 10.4 |
Rental prepayments | 0.1 | -0.1 |
Other receivables | 0.9 | 1.5 |
Total | 258.8 | 273.9 |
2024 | 2023 | |||
| Gross | Gross | |||
| carrying | Loss | carrying | Loss | |
| EUR million | amount | allowance | amount | allowance |
Not past due | 233.7 | -0.0 | 239.3 | -0.0 |
Past due 1 - 30 days | 11.4 | -0.0 | 7.7 | -0.0 |
Past due 31 - 180 days | 2.1 | -0.0 | 12.9 | -0.2 |
Past due more than 180 days | 0.1 | -0.1 | -0.0 | -0.1 |
Total | 247.3 | -0.2 | 259.8 | -0.3 |
EUR million | 2024 | 2023 |
Opening loss allowance at 1 Jan | 0.3 | 0.0 |
Net remeasurement of loss allowance | 0.1 | 0.3 |
Amounts written off during the year as uncollectible | -0.1 | - |
Unused amount reversed | -0.2 | - |
Foreign exchange rate differences | -0.0 | - |
Closing loss allowance at 31 Dec | 0.2 | 0.3 |
EUR million | 2024 | 2023 |
Trade payables | 626.2 | 607.5 |
Income tax payables | 0.3 | 0.1 |
Accrued liabilities | 12.0 | 10.8 |
| Derivatives measured at fair value through profit | ||
and loss | 0.0 | 0.6 |
VAT liabilities | 5.3 | 5.6 |
Other current liabilities | 5.5 | 2.1 |
Total | 649.4 | 626.7 |
EUR million | 2024 | 2023 |
Raw materials and consumables | 0.0 | 0.1 |
Work in progress | 0.0 | 0.0 |
Finished goods | 176.2 | 162.8 |
Total | 176.3 | 162.9 |
| Property. plant and equipment | |||||||
| 6.2. Goodwill and other intangible assets | |||||
| Other | Advance payments | ||||
| EUR million | Intangible | intangible | and construction in | ||
2024 | Goodwill | rights | assets* | progress ** | Total |
Historical cost 1 Jan 2024 | 35.2 | 15.5 | 30.8 | 2.4 | 83.9 |
Increases | - | - | 0.0 | 0.2 | 0.2 |
Decreases | - | - | -0.1 | -0.0 | -0.1 |
Impairments | - | - | - | -1.9 | -1.9 |
Reclassifications | - | - | 0.0 | -0.0 | - |
Foreign exchange rate differences | -0.0 | -0.3 | - | -0.0 | -0.3 |
Historical cost 31 Dec 2024 | 35.1 | 15.3 | 30.6 | 0.7 | 81.8 |
Accumulated amortisation 1 Jan 2024 | - | -15.1 | -17.2 | -0.5 | -32.7 |
Accumulated amortisation related to decreases and reclassifications | - | - | 0.1 | - | 0.1 |
Amortisation for the financial year | - | -0.2 | -3.6 | - | -3.8 |
Foreign exchange rate differences | - | 0.2 | - | 0.0 | 0.3 |
Accumulated amortisation 31 Dec 2024 | - | -15.0 | -20.7 | -0.5 | -36.1 |
Carrying amount 1 Jan 2024 | 35.2 | 0.5 | 13.6 | 1.9 | 51.2 |
Carrying amount 31 Dec 2024 | 35.1 | 0.3 | 10.0 | 0.2 | 45.7 |
| 2023 | |||||
Historical cost 1 Jan 2023 | 61.1 | 20.1 | 32.4 | 7.0 | 120.6 |
Increases | - | 0.1 | 0.1 | 1.8 | 2.0 |
Decreases | - | -0.6 | -1.9 | -5.9 | -8.4 |
Impairments | -21.4 | - | - | - | -21.4 |
Reclassifications | - | 0.5 | 0.1 | -0.6 | -0.0 |
Transfer to assets held for sale (note 10.3.) | -4.5 | -4.5 | - | - | -9.0 |
Foreign exchange rate differences | 0.0 | 0.0 | - | 0.0 | 0.0 |
Historical cost 31 Dec 2023 | 35.2 | 15.5 | 30.8 | 2.4 | 83.9 |
Accumulated amortisation 1 Jan 2023 | - | -17.6 | -14.9 | -6.4 | -38.9 |
Accumulated amortisation related to decreases and reclassifications | - | 0.6 | 1.9 | 5.9 | 8.4 |
Amortisation for the financial year | - | -0.6 | -4.2 | - | -4.7 |
Transfer to assets held for sale (note 10.3.) | - | 2.6 | - | - | 2.6 |
Foreign exchange rate differences | - | -0.0 | - | -0.0 | -0.0 |
Accumulated amortisation 31 Dec 2023 | - | -15.1 | -17.2 | -0.5 | -32.7 |
Carrying amount 1 Jan 2023 | 61.1 | 2.5 | 17.5 | 0.6 | 81.7 |
Carrying amount 31 Dec 2023 | 35.2 | 0.5 | 13.6 | 1.9 | 51.2 |
35.1 | ||||
Total | ||||
35.1 | ||||
| 6.3. Other non-current assets | |||
| Other shares | |||
| EUR million | and share- | Other non- | |
| 2024 | holdings | current assets | Total |
Carrying amount 1 Jan 2024 | 13.6 | 1.9 | 15.5 |
Decreases | - | -1.3 | -1.3 |
Changes in fair value | -2.6 | - | -2.6 |
| Foreign exchange rate | |||
differences | - | -0.0 | -0.0 |
Carrying amount 31 Dec 2024 | 11.0 | 0.7 | 11.7 |
| 2023 | |||
Carrying amount 1 Jan 2023 | 34.2 | 4.0 | 38.3 |
Increases | - | -2.1 | -2.1 |
Decreases | -20.6 | - | -20.6 |
| Foreign exchange rate | |||
differences | - | 0.0 | 0.0 |
Carrying amount 31 Dec 2023 | 13.6 | 1.9 | 15.5 |
| Right-of-use assets | ||
EUR million | 2024 | 2023 |
Real estate | 10.8 | 7.5 |
IT equipment | 0.0 | 0.0 |
Vehicles | 1.2 | 1.0 |
Other machinery and equipment | 0.1 | 0.1 |
Total | 12.0 | 8.6 |
| Lease liabilities | ||
EUR million | 2024 | 2023 |
Current | 2.7 | 2.8 |
Non-current | 9.7 | 6.1 |
Total | 12.3 | 8.9 |
EUR million | 2024 | 2023 |
| Depreciation charge of right-of-use assets | ||
Real estate | -2.3 | -2.6 |
IT equipment | -0.0 | -0.0 |
Vehicles | -0.6 | -0.4 |
Other machinery and equipment | -0.0 | -0.0 |
Total depreciation | -3.0 | -3.1 |
Interest expense (included in financial expenses) | -0.3 | -0.3 |
| Expense relating to short-term leases | ||
| Expense relating to short-term leases | ||
(included in other operating expenses) | -0.1 | -0.1 |
| Expense relating to leases of low-value assets | ||
(included in other operating expenses) | -0.2 | -0.3 |
Gains from changes in leases (included in other operating income) | 0.0 | 0.1 |
| Financial income and expenses | ||
EUR million | 2024 | 2023 |
| Financial income | ||
Interest income on financial assets measured at amortised cost | 1.6 | 1.8 |
| Interest income on financial assets and liabilities | ||
recognised at fair value | 0.1 | 0.0 |
Changes in fair values of financial assets and liabilities recognised at fair value, net | - | 0.1 |
| Foreign exchange rate gains from financial assets | ||
and liabilities measured at amortised cost, net | 1.3 | - |
Total | 3.0 | 2.0 |
| Financial expenses | ||
| Interest expenses on financial liabilities measured | ||
at amortised cost | 4.0 | 5.0 |
Interest expenses on leases | 0.3 | 0.3 |
Changes in fair values of financial assets and liabilities recognised at fair value, net | 1.7 | - |
| Foreign exchange rate losses on financial assets | ||
and liabilities measured at amortised cost, net | - | 0.2 |
Other financial expenses | 4.4 | 4.1 |
Total | 10.4 | 9.6 |
Financial income and expenses, total | -7.3 | -7.6 |
| Financial assets and liabilities by category | |||||||
2024 | 2023 | ||||||
EUR million | Note | Fair value | Book value | Hierarchy | Fair value | Book value | Hierarchy |
Derivatives designated as hedges | 8.3 | 0.8 | 0.8 | Level 2 | 1.8 | 1.8 | Level 2 |
Financial assets recognised at fair value through profit and loss | |||||||
| Derivatives measured at fair value through profit | |||||||
and loss | 8.3. | 0.5 | 0.5 | Level 2 | 0.9 | 0.9 | Level 2 |
Other investments measured at fair value through OCI | 6.3. | 11.0 | 11.0 | Level 3 | 13.6 | 13.6 | Level 3 |
Trade receivables for sale | 5.1. | 13.1 | 13.1 | Level 2 | 8.0 | 8.0 | Level 2 |
| Financial assets measured at amortised cost | |||||||
Cash equivalents | 113.5 | 113.5 | Level 2 | 138.4 | 138.4 | Level 2 | |
Trade receivables and other receivables | 5.1. | 236.7 | 236.7 | Level 2 | 254.0 | 254.0 | Level 2 |
Financial assets, total | 375.6 | 375.6 | 416.8 | 416.8 | |||
Derivatives designated as hedges | 8.3. | 0.5 | 0.5 | Level 2 | 0.4 | 0.4 | Level 2 |
Financial liabilities recognised at fair value through profit and loss | |||||||
| Derivatives measured at fair value through profit | |||||||
and loss | 8.3. | 0.0 | 0.0 | Level 2 | 0.6 | 0.6 | Level 2 |
| Financial liabilities measured at amortised cost | |||||||
Non-current interest-bearing liabilities | 39.7 | 39.7 | Level 2 | 7.1 | 7.1 | Level 2 | |
Current interest-bearing liabilities | 36.4 | 36.4 | Level 2 | 110.7 | 110.7 | Level 2 | |
Trade payables and other current liabilities | 5.3. | 643.6 | 643.6 | Level 2 | 620.2 | 620.2 | Level 2 |
Financial liabilities, total | 720.2 | 720.2 | 738.9 | 738.9 |
EUR million | 2024 | 2023 |
Carrying amount 1 Jan | 13.6 | 34.2 |
Change in fair value | -2.6 | -20.6 |
Carrying amount 31 Dec | 11.0 | 13.6 |
| Net debt | ||
EUR million | 2024 | 2023 |
Loans from financial institutions | 30.0 | 1.0 |
Lease liabilities | 9.7 | 6.1 |
Non-current interest-bearing liabilities | 39.7 | 7.1 |
Loans from financial institutions | 1.0 | 58.1 |
Issued commercial papers | 24.8 | 39.3 |
Advances received from pharmacies | 7.9 | 10.4 |
Lease liabilities | 2.7 | 2.8 |
Current interest-bearing liabilities | 36.4 | 110.7 |
Interest-bearing liabilities, total | 76.1 | 117.7 |
Cash and cash equivalents | 113.5 | 138.4 |
Net debt | -37.4 | -20.6 |
| Non-current | ||
EUR million | 2024 | 2023 |
Loans from financial institutions | 30.0 | 1.0 |
Lease liabilities | 9.7 | 6.1 |
Total | 39.7 | 7.1 |
| Current | ||
EUR million | 2024 | 2023 |
Loans from financial institutions | 1.0 | 58.1 |
Issued commercial papers | 24.8 | 39.3 |
Advances received from pharmacies | 7.9 | 10.4 |
Lease liabilities | 2.7 | 2.8 |
Total | 36.4 | 110.7 |
| Interest-bearing liabilities by currency | ||
EUR million | 2024 | 2023 |
EUR | 66.8 | 84.0 |
SEK | 9.3 | 33.8 |
Total | 76.1 | 117.7 |
| Change in net debt | ||||||
| Loans from | ||||||
| EUR million | financial | Commercial | Advances from | Cash and cash | ||
| 2024 | institutions | papers | pharmacies | Lease liabilities | equivalents | Total |
Carrying value, at 1 January 2024 | -59.1 | -39.3 | -10.4 | -8.9 | 138.4 | 20.6 |
| Change in net debt, cash: | ||||||
Proceeds from non-current loans | -30.0 | - | - | - | - | -30.0 |
Repayments of non-current loans | 1.0 | - | - | - | - | 1.0 |
Repayment of current loans | 56.9 | - | - | - | - | 56.9 |
Repayments of lease liabilities | - | - | - | 3.1 | - | 3.1 |
Change in other current liabilities | - | 14.5 | 2.4 | - | - | 17.0 |
Change in cash and cash equivalents | - | - | - | - | -24.9 | -24.9 |
Cash flows, total | 27.9 | 14.5 | 2.4 | 3.1 | -24.9 | 23.1 |
| Change in net debt, non-cash: | ||||||
Change in lease liabilities | - | - | - | -6.8 | - | -6.8 |
Foreign exchange adjustments | 0.3 | - | - | 0.2 | -0.0 | 0.5 |
Non-cash movements, total | 0.3 | - | - | -6.6 | -0.0 | -6.3 |
Carrying value, at 31 December 2024 | -31.0 | -24.8 | -7.9 | -12.3 | 113.5 | 37.4 |
| Loans from | ||||||
| EUR million | financial | Commercial | Advances from | Cash and cash | ||
| 2023 | institutions | papers | pharmacies | Lease liabilities | equivalents | Total |
Carrying value, at 1 January 2023 | -61.1 | -49.8 | -11.8 | -14.3 | 160.6 | 23.7 |
| Change in net debt, cash: | ||||||
Repayments of non-current loans | 2.0 | - | - | - | - | 2.0 |
Repayments of lease liabilities | - | - | - | 3.5 | - | 3.5 |
Change in other current liabilities | - | 10.5 | 1.4 | - | - | 11.9 |
Change in cash and cash equivalents | - | - | - | - | -22.3 | -22.3 |
Cash flows, total | 2.0 | 10.5 | 1.4 | 3.5 | -22.3 | -4.9 |
| Change in net debt, non-cash: | ||||||
Change in lease liabilities | - | - | - | 1.6 | - | 1.6 |
Changes arising from losing control of subsidiaries | - | - | - | 0.2 | 0.2 | |
Foreign exchange adjustments | -0.1 | - | - | 0.1 | -0.0 | 0.1 |
Non-cash movements, total | -0.1 | - | - | 1.9 | -0.0 | 1.8 |
Carrying value, at 31 December 2023 | -59.1 | -39.3 | -10.4 | -8.9 | 138.4 | 20.6 |
| Maturity distribution of financial assets and liabilities | |||||
| 31 Dec 2024 | |||||
EUR million | 2025 | 2026 | 2027 | 2028> | Total |
| Interest-bearing | |||||
Loans from financial institutions and commercial paper loans | 25.8 | - | 30.0 | - | 55.8 |
Lease liabilities | 2.7 | 2.7 | 2.2 | 4.7 | 12.3 |
Advance payments received | 7.9 | - | - | - | 7.9 |
| Non-interest-bearing | |||||
| Trade payables and other current | |||||
liabilities | 643.6 | - | - | - | 643.6 |
Receivables from interest rate swaps | -0.2 | -0.3 | - | -0.3 | -0.8 |
Liabilities from interest rate swaps | - | - | 0.5 | - | 0.5 |
| Receivables from foreign currency | |||||
derivatives | -104.8 | - | - | - | -104.8 |
| Payables on foreign currency | |||||
derivatives | 104.4 | - | - | - | 104.4 |
Total | 679.4 | 2.4 | 32.7 | 4.4 | 718.9 |
Interest payments | 2.1 | 1.5 | 1.4 | 0.2 | 5.2 |
| 31 Dec 2023 | |||||
EUR million | 2024 | 2025 | 2026 | 2027> | Total |
| Interest-bearing | |||||
Loans from financial institutions and commercial paper loans | 97.5 | 1.0 | - | - | 98.5 |
Lease liabilities | 2.8 | 2.4 | 2.1 | 1.6 | 8.9 |
Advance payments received | 10.4 | - | - | - | 10.4 |
| Non-interest-bearing | |||||
| Trade payables and other current | |||||
liabilities | 620.2 | - | - | - | 620.2 |
Receivables from interest rate swaps | -0.3 | -0.8 | -1.1 | - | -2.2 |
Liabilities from interest rate swaps | - | - | - | 0.4 | 0.4 |
| Receivables from foreign currency | |||||
derivatives | -76.0 | - | - | - | -76.0 |
| Payables on foreign currency | |||||
derivatives | 76.1 | - | - | - | 76.1 |
Total | 730.5 | 2.6 | 1.0 | 2.0 | 736.1 |
Interest payments | 3.6 | 0.2 | 0.1 | 0.0 | 3.8 |
| Derivatives | |||
| EUR million | Positive fair | Negative | Nominal |
| 2024 | value | fair value | value |
Derivatives recognised as cash flow hedges | |||
Interest rate swaps, in hedge accounting | 0.8 | 0.5 | 82.4 |
Derivatives measured at fair value through profit and loss | |||
| Foreign currency forward and swap | |||
contracts | 0.5 | 0.0 | 104.4 |
Total | 1.3 | 0.5 | 186.7 |
| 2023 | |||
Derivatives recognised as cash flow hedges | |||
Interest rate swaps, in hedge accounting | 1.8 | 0.4 | 54.1 |
Derivatives measured at fair value through profit and loss | |||
Interest rate swaps | 0.3 | - | 10.8 |
| Foreign currency forward and swap | |||
contracts | 0.6 | 0.6 | 75.5 |
Total | 2.8 | 1.0 | 140.4 |
| Share capital | ||||
Share capital | A shares | B shares | Total | |
Number of shares 1 Jan 2024 | pcs | 53,748,313 | 127,737,900 | 181,486,213 |
Conversion of A shares to B shares | pcs | - | - | 0 |
Number of shares 31 Dec 2024 | pcs | 53,748,313 | 127,737,900 | 181,486,213 |
Treasury shares 31 Dec 2024 | pcs | 63,650 | 12,062 | 75,712 |
Votes 31 Dec 2024 | pcs | 1,074,966,260 | 127,737,900 | 1,202,704,160 |
Share capital per share class 31 Dec 2024 | EUR million | 43.8 | 104.1 | 147.9 |
Percentage from the total shares | % | 29.6 | 70.4 | 100.0 |
Percentage from the total votes | % | 89.4 | 10.6 | 100.0 |
Number of shares 1 Jan 2023 | pcs | 53,748,313 | 127,737,900 | 181,486,213 |
Conversion of A shares to B shares | pcs | - | - | 0 |
Number of shares 31 Dec 2023 | pcs | 53,748,313 | 127,737,900 | 181,486,213 |
Treasury shares 31 Dec 2023 | pcs | 63,650 | 23,776 | 87,426 |
Votes 31 Dec 2023 | pcs | 1,074,966,260 | 127,737,900 | 1,202,704,160 |
Share capital per share class 31 Dec 2023 | EUR million | 43.8 | 104.1 | 147.9 |
Percentage from the total shares | % | 29.6 | 70.4 | 100.0 |
Percentage from the total votes | % | 89.4 | 10.6 | 100.0 |
EUR million | 2024 | 2023 | ||
Parent company share capital 31 Dec | 147.9 | 147.9 | ||
Elimination of the revaluation of subsidiary shares in the consolidated financial statements | -111.7 | -111.7 | ||
Consolidated share capital 31 Dec | 36.2 | 36.2 |
| Earnings per share | ||
| Profit for the period | ||
EUR million | 2024 | 2023 |
Profit attributable to equity owners of the parent | -20.1 | -20.7 |
| Average number of outstanding | ||
| shares pcs | ||
Basic | 181,408,101 | 181,389,629 |
Diluted | 181,422,563 | 181,422,563 |
| Earnings per share, EUR | ||
Basic | -0.11 | -0.11 |
Diluted | -0.11 | -0.11 |
| Income taxes | ||
EUR million | 2024 | 2023 |
Taxes for current year | 3.6 | 3.1 |
Taxes for previous years | 0.0 | 0.9 |
Deferred taxes | -2.1 | -1.0 |
Total | 1.5 | 3.1 |
| Taxes related to other comprehensive income | |||
| EUR million | |||
2024 | Before taxes | Tax effect | After taxes |
Cash flow hedge | -1.2 | -0.2 | -0.9 |
| Financial assets recognised | |||
at fair value through other comprehensive income | -2.6 | - | -2.6 |
Actuarial gains and losses | 0.2 | 0.0 | 0.1 |
Translation differences | -1.7 | - | -1.7 |
Total | -5.3 | -0.2 | -5.1 |
| 2023 | |||
Cash flow hedge | -1.8 | -0.4 | -1.5 |
| Financial assets recognised | |||
at fair value through other comprehensive income | -20.6 | - | -20.6 |
Actuarial gains and losses | -1.4 | -0.3 | -1.1 |
Translation differences | 0.0 | - | 0.0 |
Total | -23.8 | -0.7 | -23.1 |
| Tax rate reconciliation | |||
EUR million | 2024 | 2023 | |
Profit before taxes | -18.6 | -17.6 | |
| Corporate income taxes calculated at Finnish tax | |||
rate | -3.7 | -3.5 | |
Effect of different tax rates of foreign subsidiaries | -0.1 | -0.0 | |
Impairment of goodwill - non-deductible | - | 4.3 | |
Non-deductible expenses and tax-exempt income | 0.2 | 0.4 | |
Share of result in joint venture | 5.1 | 1.0 | |
| Adjustments recognised for taxes of previous | |||
years | - | 0.9 | |
Other items | -0.0 | -0.0 | |
Income taxes in the income statement | 1.5 | 3.1 | |
Effective tax rate | -8.1% | -17.4% |
| Deferred tax assets and liabilities | ||||||
| Items recognised in | Items recognised in other | Classified as | Translation | |||
2024 | 1 Jan | income statement | comprehensive income | held for sale | differences | 31 Dec |
| Deferred tax assets | ||||||
Confirmed losses | - | 0.1 | - | -0.1 | - | - |
Pension liabilities | 0.7 | -0.1 | -0.0 | - | 0.0 | 0.6 |
Employee benefits | 0.3 | 0.0 | - | - | -0.0 | 0.3 |
Lease agreements | 1.9 | 0.7 | - | 0.1 | -0.1 | 2.6 |
Other temporary differences | 0.0 | 1.3 | - | - | - | 1.4 |
Deferred tax assets | 3.0 | 2.1 | -0.0 | -0.1 | -0.1 | 4.9 |
Set-off of tax | -2.6 | -4.3 | ||||
Net deferred tax assets | 0.4 | 0.6 | ||||
| Deferred tax liabilities | ||||||
Depreciation difference and other untaxed reserves | 3.8 | -1.2 | - | 0.2 | -0.1 | 2.7 |
Acquisitions | -0.1 | - | - | - | - | -0.1 |
Lease agreements | 1.8 | 0.7 | - | 0.0 | -0.0 | 2.5 |
Other temporary differences | 0.0 | 0.1 | - | - | - | 0.1 |
Deferred tax liabilities | 5.5 | -0.5 | - | 0.2 | -0.2 | 5.1 |
Set-off of tax | -2.6 | -4.3 | ||||
Net deferred tax liabilities | 2.9 | 0.8 | ||||
| Items recognised in | Items recognised in other | Discontinued | Translation | |||
2023 | 1 Jan | income statement | comprehensive income | operations | differences | 31 Dec |
| Deferred tax assets | ||||||
Inventories | - | 0.8 | - | -0.8 | - | - |
Pension liabilities | 0.7 | -0.2 | 0.3 | - | 0.0 | 0.7 |
Employee benefits | 0.2 | 0.0 | - | - | - | 0.3 |
Lease agreements | 3.1 | -1.1 | - | -0.1 | 0.0 | 1.9 |
Other temporary differences | 0.0 | -0.3 | 0.4 | -0.0 | 0.0 | 0.0 |
Deferred tax assets | 4.0 | -0.8 | 0.7 | -0.9 | 0.0 | 3.0 |
Set-off of tax | -2.8 | -2.6 | ||||
Net deferred tax assets | 1.2 | 0.4 | ||||
| Deferred tax liabilities | ||||||
Depreciation difference and other untaxed reserves | 4.9 | -0.9 | - | -0.2 | 0.0 | 3.8 |
Acquisitions | -0.1 | -0.0 | - | - | - | -0.1 |
Lease agreements | 2.8 | -1.0 | - | -0.0 | 0.0 | 1.8 |
Other temporary differences | 0.1 | 0.0 | - | -0.1 | - | 0.0 |
Deferred tax liabilities, total | 7.7 | -1.9 | - | -0.4 | 0.0 | 5.5 |
Set-off of tax | -2.8 | -2.6 | ||||
Net deferred tax liabilities | 4.9 | 2.9 |
Group | Parent company | ||||
| Owner- | Owner- | ||||
31 Dec 2024 | Domicile | ship % Share % | ship % Share % | ||
| Parent company Oriola | |||||
Corporation | Finland | ||||
Oriola Finland Oy | Finland | 100 | 100 | 100 | 100 |
Oriola Sweden AB | Sweden | 100 | 100 | 100 | 100 |
Svensk dos AB | Sweden | 100 | 100 | 100 | 100 |
Pharmaservice Oy | Finland | 100 | 100 | 100 | 100 |
Group | Parent company | ||||
| Owner- | Owner- | ||||
31 Dec 2023 | Domicile | ship % Share % | ship % Share % | ||
| Parent company Oriola | |||||
Corporation | Finland | ||||
Oriola Finland Oy | Finland | 100 | 100 | 100 | 100 |
Oriola Sweden AB | Sweden | 100 | 100 | 100 | 100 |
Svensk dos AB | Sweden | 100 | 100 | 100 | 100 |
Pharmaservice Oy | Finland | 100 | 100 | 100 | 100 |
Oriola Sweden AB | Sweden | 100 | 100 | 100 | 100 |
| ICTHS Health | |||||
Support AB | Sweden | 100 | 100 | ||
EUR million | 2024 | 2023 |
Net sales* | 360.0 | 314.7 |
Purchases of goods and services | 0.8 | 0.4 |
Trade and other receivables | 70.0 | 70.5 |
Trade and other payables | 4.3 | 0.8 |
Commitments | - | 0.1 |
| Key management benefits | ||
EUR thousand | 2024 | 2023 |
Salaries and other short-term employee benefits | 2,173.2 | 2,515.9 |
Termination benefits | 408.0 | 159.0 |
Share-based payments | 132.5 | 97.4 |
Total | 2,713.6 | 2,772.3 |
| Employee benefits to President and CEO | ||
EUR thousand | 2024 | 2023 |
| Katarina Gabrielson | ||
Basic salary | 427.5 | 418.1 |
Bonuses | - | 204.9 |
Share-based payments | 16.4 | 3.6 |
Pension expenses (statutory) | 36.1 | 33.0 |
Pension expenses (voluntary) | 42.0 | 41.9 |
Employee benefits to President and CEO total | 522.1 | 701.4 |
| Employee benefits to other members of the Oriola Management | ||
| Team | ||
EUR thousand | 2024 | 2023 |
Basic salary | 1,155.1 | 1,001.7 |
Bonuses | - | 337.1 |
Share-based payments | 5.1 | 5.1 |
Termination expenses * | 408.0 | 159.0 |
Pension expenses (statutory) | 243.2 | 238.1 |
Pension expenses (voluntary) | 23.6 | 23.5 |
Total | 1,835.0 | 1,764.4 |
| Remuneration of the members of the Board of Directors | ||
EUR thousand | 2024 | 2023 |
Heikki Westerlund, Chairman* | 85.5 | 75.0 |
Harri Pärssinen, Vice Chairman | 52.5 | 50.0 |
Petra Axdorff** | 43.0 | - |
Ann Carlsson Meyer** | 41.0 | - |
Nina Mähönen | 43.0 | 41.5 |
Yrjö Närhinen* | 47.0 | 39.5 |
Ellinor Persdotter Nilsson* | 42.5 | 38.0 |
Eva Nilsson Bågenholm*** | 2.0 | 50.0 |
EUR thousand | 2024 | 2023 |
Juko-Juho Hakala**** | - | 7.0 |
Lena Ridström**** | - | 2.5 |
Panu Routila**** | - | 4.5 |
Total | 356.5 | 308.0 |
EUR million | 2024 | 2023 |
Property, plant and equipment | 2.3 | 2.4 |
Goodwill | 4.5 | 4.5 |
Other intangible assets | 1.8 | 1.9 |
Deferred tax assets | 0.6 | 0.5 |
Inventories | 1.5 | 1.2 |
EUR million | 2024 | 2023 |
Trade and other receivables | 2.4 | 1.5 |
Cash and cash equivalents | 0.0 | 0.0 |
Total assets | 13.1 | 12.0 |
| EUR million | ||
Deferred tax liabilities | 0.1 | 0.1 |
Current interest-bearing liabilities | - | 0.2 |
Current trade and other payables | 1.7 | 1.5 |
Total liabilities | 1.8 | 1.8 |
EUR million | 2024 | 2023 |
Carrying amount 1 Jan | 235.4 | 240.4 |
Share of result for the period | -24.8 | -4.8 |
Foreign exchange rate differences | 0.3 | -0.2 |
Carrying amount 31 Dec | 210.9 | 235.4 |
| Swedish Pharmacy Holding AB | ||
Balance sheet EUR million | 31 Dec 2024 | 31 Dec 2023 |
| Current assets | ||
Cash and cash equivalents | 3.8 | 13.5 |
Other current assets | 156.5 | 157.2 |
Current assets total | 160.3 | 170.6 |
Non-current assets | 507.8 | 587.9 |
| Current liabilities | ||
Trade payables | 114.2 | 114.1 |
Other current liabilities | 48.7 | 59.9 |
Current liabilities total | 162.8 | 174.0 |
Non-current liabilities | 104.8 | 116.5 |
Net assets total | 400.4 | 468.1 |
| Reconciliation to carrying amounts | ||
EUR million | 31 Dec 2024 | 31 Dec 2023 |
Net assets 1 Jan | 468.1 | 474.1 |
Change in reserves | -5.0 | - |
Adjustment to the opening balance | 1.7 | 2.7 |
Translation differences | -14.7 | 0.8 |
Loss for the period | -49.7 | -9.5 |
Net assets 31 Dec | 400.4 | 468.1 |
Group's share in joint venture | 50% | 50% |
Group’s share of net assets | 200.2 | 234.0 |
Translation differences | 7.4 | -0.4 |
Other | 3.3 | 1.8 |
Carrying amount 31 Dec | 210.9 | 235.4 |
| Swedish Pharmacy Holding AB | ||
Income statement EUR million | 2024 | 2023 |
Net sales | 1,151.1 | 1,126.9 |
Depreciation. amortisation and impairment losses | -84.7 | -45.6 |
Net interest expenses | -5.0 | -3.9 |
Income taxes | 2.6 | 2.3 |
Result for the period | -49.7 | -9.5 |
EUR million | 2024 | 2023 |
| Commitments for own liabilities | ||
Guarantees on behalf of subsidiaries | 7.1 | 6.6 |
Guarantees on behalf of other companies | - | 0.1 |
Mortgages on company assets | 2.0 | 1.9 |
Other guarantees and liabilities | 1.7 | 3.8 |
Total | 10.9 | 12.4 |
| Committed future minimum lease payments: | ||
EUR million | 2024 | 2023 |
Within one year | 0.7 | 0.5 |
One to five years | 0.3 | 0.4 |
Total | 0.9 | 0.9 |